Low molecular weight heparin vs vitamin K antagonist (VKA)
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 3.11 [0.13, 73.11]2 studies · 289 participantsVery low